Nvidia, AMD to pay 15% of China chip sales revenue to US govt- FT
CAMBRIDGE, MA — Joshua B. Cohen, Co-Chief Executive Officer of Amylyx Pharmaceuticals , Inc. (NASDAQ:AMLX), recently sold 21,490 shares of the company’s common stock. The transaction, which took place on March 31, 2025, was valued at approximately $74,482, with shares sold at a weighted average price of $3.4659. The stock, currently trading at $3.78, has shown resilience with a 27% gain over the past year despite recent volatility. According to InvestingPro analysis, the company appears undervalued based on its Fair Value metrics.
This sale was executed to cover tax withholding obligations related to the vesting of restricted stock units. As noted in the filing, these sales were automatic and not at Cohen’s discretion. For deeper insights into AMLX’s financial health and detailed valuation analysis, check out the comprehensive research report available on InvestingPro. Following this transaction, Cohen retains direct ownership of 3,355,280 shares of Amylyx Pharmaceuticals, demonstrating continued significant alignment with the $296 million market cap company.
In other recent news, Amylyx Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold on its Phase 1 trial for AMX0114, a potential treatment for amyotrophic lateral sclerosis (ALS). This decision allows the company to proceed with patient screening, enrollment, and dosing at trial sites across the United States. The trial, known as LUMINA, will also commence in Canada early this year and is designed as a multicenter, randomized, placebo-controlled study. It aims to evaluate the safety and biological activity of AMX0114, targeting calpain-2, a protein associated with neurodegenerative processes. The trial will involve approximately 48 individuals with ALS, who will be randomized to receive either the investigational drug or a placebo. Amylyx plans to monitor changes in neurofilament light (NfL) levels, a biomarker for ALS, during the trial. The company anticipates sharing early cohort data from the LUMINA trial within the year. These developments are part of Amylyx’s ongoing efforts to address significant unmet medical needs in neurodegenerative diseases.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.